NICE chary of Aubagio, wants more proof of cost-benefit
This article was originally published in Scrip
Executive Summary
The UK health technology assessment body, NICE, is "minded not to recommend" Sanofi's multiple sclerosis pill Aubagio (teriflunomide). It has issued draft guidance on the product, calling for further clarification and analyses before making a final decision.